Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency
Abstract Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adrenal insufficiency (AI) can be life-threatening especially in patients with d...
Main Authors: | Katsunori Manaka, Junichiro Sato, Maki Takeuchi, Kousuke Watanabe, Hidenori Kage, Taketo Kawai, Yusuke Sato, Takuya Miyagawa, Daisuke Yamada, Haruki Kume, Shinichi Sato, Takahide Nagase, Taroh Iiri, Masaomi Nangaku, Noriko Makita |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-06-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-91032-6 |
Similar Items
-
Nose size indicates maximum penile length
by: Hiroshi Ikegaya, et al.
Published: (2021-02-01) -
Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor.
by: Kousuke Watanabe, et al.
Published: (2018-01-01) -
Cerebral Arterial Air Embolism after Diagnostic Flexible Fiberoptic Bronchoscopy: A Case Report and Review of the Literature
by: Keita Maemura, et al.
Published: (2018-01-01) -
Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML
by: Kousuke Watanabe, et al.
Published: (2020-01-01) -
Are call centers sweatshops?
by: Hidenori Sato
Published: (2018-09-01)